Virginia Tech Carilion Research Institute (VTCRI) is set to serve as the first nonclinical research environment to use INSIGHTEC’s Exablate Neuro solution as part an endeavor to develop noninvasive treatments for brain disorders.
The focused ultrasound solution, paired with Siemens MR imaging, will be used to research potential applications for cancer treatments, such as for brain tumors, targeted disruption of the blood-brain barrier in the delivery of therapeutics to the brain, and the use of neuromodulation in treating psychiatric disorders.
"We share a common vision, a culture of discovery and openness, and a commitment to study and develop scientifically validated technological innovations, to treat patients with otherwise untreatable brain disorders," Michael Friedlander, VTCRI executive director and Virginia Tech's vice president for health sciences and technology, said in a statement.
The solution is already FDA cleared for treating essential tremor
and hit its 1,000 patient mark
this past August for such treatment. The FDA also approved
its use in a pivotal study for treating individuals with advanced Parkinson’s disease.
Exablate Neuro utilizes more than 1,000 ultrasound beams focused on a single spot to ablate tissue with no incisions, and without damaging surrounding structures.
The partnership has been facilitated by the Focused Ultrasound Foundation.
"Collaboration with academic centers of excellence, such as VTCRI, is a key component of INSIGHTEC's heritage of innovation,” Maurice R. Ferré, M.D., INSIGHTEC's CEO and chairman of the board, said in a statement. “Collaboration fuels the scientific breakthroughs that ultimately improve patient lives."
VTCRI and INSIGHTEC did not respond for comment.